Cancer doctors in the US have launched a new scheme that aims to improve care by setting out electronic health record standards. There are 15 million people with cancer in the US b
Finding targeted therapies for pancreatic cancer has long been an issue for pharma, meaning that for decades the only real option has been a course of chemotherapy, with unpleasant side-eff
Roche and Merck & Co have got their respective immunotherapies Tecentriq and Keytruda approved in bladder cancer – but the problem of low response rates remains. At the ASCO an
Sanofi’s plans for a comeback in cancer have taken a step forward with new data on its anti-CD38 candidate isatuximab in multiple myeloma, already filed in the US and Europe. Headl
Only 3% of patients with cancer in the US enrol on a clinical trial – and the American Society of Clinical Oncology (ASCO) is concerned that outdated and restrictive eligibility criteria co
Novartis’ Kisqali has become the first drug in the CDK 4/6 inhibitor class to improve overall survival in metastatic breast cancer. The results of the MONALEESA-7 trial – reported
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.